As for expression of Ob-R in breast cancer subtypes, our results differ from those reported elsewhere (28–30), probably because of differences in the score and methodology used to evaluate Ob-R expression: one study used a score of 5% for positivity while in our study the score was 50% and, on the other hand, some studies analyzed Ob-R in cell lines while our study assessed breast tumors directly. This evidence concerns the gene LEPR and breast carcinoma.